Axiom Biosciences, a San Diego-based firm developing AI-driven therapies for infant brain injuries, aims to raise US$200 million in a 2027 Hong Kong IPO.
Key facts
- •Axiom Biosciences is targeting a minimum of US$200 million in its 2027 Hong Kong IPO.
- •The company plans to follow its Hong Kong debut with a secondary US listing in 2029.
- •Axiom, founded in 2018, is based in San Diego and focuses on AI-driven therapies for infant brain injuries.
- •The company has secured US$17.17 million in funding over 13 rounds, according to CB Insights.
- •Axiom claims it will be the first US-based biotech firm to list on the Hong Kong exchange.
Axiom Biosciences, a US-based biotechnology company specializing in experimental therapies for newborns with severe brain injuries, has announced plans for an initial public offering in Hong Kong. The firm is targeting at least US$200 million in the 2027 listing, with intentions to pursue a secondary listing in the United States by 2029.
By the numbers
Strategic Rationale for Hong Kong Listing
Founder and CEO Remo Moomiaie-Qajar stated that the company chose Hong Kong due to the presence of deep biotechnology capital and clinical partners in the region. Moomiaie-Qajar noted that healthcare companies listing in Hong Kong have outperformed Nasdaq-listed peers in recent years, describing the Hong Kong market as more mature in its handling of public biotech firms.
Company Background and Funding
Founded in 2018 and headquartered in San Diego, California, Axiom Biosciences utilizes artificial intelligence to develop its treatments. According to data from CB Insights, the company has raised US$17.17 million across 13 funding rounds to date. The firm stated it expects to be the first US-operating biotech company to list in Hong Kong.
Timeline
- 2018Axiom Biosciences was founded.
- 2027The company plans to conduct an initial public offering in Hong Kong.
- 2029The company intends to pursue a secondary listing in the US.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by SCMP Business.
